Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 10,000 shares of the company's stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total value of $400,300.00. Following the completion of the transaction, the chief financial officer now directly owns 101,959 shares of the company's stock, valued at $4,081,418.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Jack Anders also recently made the following trade(s):
- On Monday, March 18th, Jack Anders sold 1,261 shares of Revolution Medicines stock. The stock was sold at an average price of $31.58, for a total value of $39,822.38.
Revolution Medicines Price Performance
Shares of RVMD opened at $40.20 on Friday. Revolution Medicines, Inc. has a 52-week low of $15.44 and a 52-week high of $40.21. The stock's 50-day simple moving average is $33.04 and its 200 day simple moving average is $28.30.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.29). The firm had revenue of $0.74 million for the quarter, compared to the consensus estimate of $1.20 million. The company's revenue for the quarter was down 95.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.63) EPS. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.18 earnings per share for the current year.
Institutional Inflows and Outflows
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
Several large investors have recently bought and sold shares of the company. Manchester Capital Management LLC bought a new stake in shares of Revolution Medicines during the 4th quarter valued at about $80,000. China Universal Asset Management Co. Ltd. lifted its position in Revolution Medicines by 101.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,802 shares of the company's stock valued at $78,000 after purchasing an additional 1,409 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Revolution Medicines in the 1st quarter worth approximately $104,000. Fred Alger Management LLC purchased a new position in Revolution Medicines in the 3rd quarter worth approximately $126,000. Finally, Federated Hermes Inc. bought a new position in shares of Revolution Medicines in the 3rd quarter worth $126,000. 94.34% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently commented on RVMD shares. Needham & Company LLC reiterated a "buy" rating and set a $46.00 target price (up from $36.00) on shares of Revolution Medicines in a research note on Monday, April 8th. Oppenheimer boosted their target price on shares of Revolution Medicines from $43.00 to $45.00 and gave the company an "outperform" rating in a research note on Friday, April 12th. Raymond James raised shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and increased their target price for the company from $36.00 to $48.00 in a research report on Wednesday, April 10th. Bank of America raised shares of Revolution Medicines from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $31.00 to $34.00 in a report on Friday, January 5th. Finally, Piper Sandler assumed coverage on Revolution Medicines in a report on Monday, March 11th. They set an "overweight" rating and a $43.00 price objective for the company. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $41.20.
Read Our Latest Stock Report on Revolution Medicines
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
